---
date: 2026-10-11
source: user
asked_by: user
capture: verbatim
original_location: three chat messages from the user on 2026-10-11 in a cursor-agent session (a draft figure prompt written in a ChatGPT web thread; the answers to four multiple-choice questions the agent asked; the go-ahead with an illustrative ChatGPT image that uses no real data); recorded here the same day
---

# 2026-10-11 the feature-space explainer figure ("The same cells can be represented in different feature spaces")

Each quoted text is verbatim (wording and typos kept). The first message is quoted whole below; between the first and the last message the agent proposed a revised prompt in chat and asked four multiple-choice questions, whose answers follow the asks.

- [A-20261011-14] "Let's iterate on this prompt before implementation. How this plot concept which is already good can be further implemented/improved by looking at the recent reports in sc_classification/scripts/mrd_stage0_2/research/reports/2026-10-08_questions_report?" -> W5.11, W0.13, D30
- [A-20261011-15] "# Task: Generate a data-grounded illustration of cell × gene and cell × factor representations" (the draft prompt, quoted whole below) -> W5.11, W0.13, D30
- [A-20261011-16] "Can you go ahead and build it? See attached for the illustrative example from webversion chatgpt. Not based on real data, I like the dividing the cells to different patients and other properties." -> W5.11, D30

## The user's answers to the agent's four questions (option labels as shown)

- PC8's sign: "Oriented ×(−1) as in the report (Figures 5a, 19, 20), marked in the column header (Recommended)".
- Patients: "P02, P03, P04, P09 plus P01 as the low-prevalence, high-leverage contrast (Recommended)".
- Extensions (multiple choice; all four selected): "None; mention protein and FA in the caption only (Recommended)"; "Surface protein (CLR) as a third, measured feature space with a dashed 'read, not fit' link to PC8"; "FA K=40 as a second factor matrix for the same cells"; "One recipient-origin normal cell per patient, so origin and label visibly differ". Read by the agent as: a core figure without extensions plus an extended review figure with all three.
- Where it lives: "Standalone paper Fig1A candidate; code in W5 as new backlog line W5.9 (Recommended)". W5.9 and W5.10 were taken the same day by another session, so the line is W5.11.

The attached image (kept in the chat only) is a ChatGPT illustration with invented data: a cell × gene heatmap and a cell × factor heatmap side by side, each with a patient band (P01-P03), a malignant label column and a cell-type column, a Stage 1 arrow between them, and four "view from the cell / gene / factor angle" panels below.

## The first message, quoted whole

> Let's iterate on this prompt before implementation. How this plot concept which is already good can be further implemented/improved by looking at the recent reports in sc_classification/scripts/mrd_stage0_2/research/reports/2026-10-08_questions_report? 
> # Task: Generate a data-grounded illustration of cell × gene and cell × factor representations
>
> ## Objective
>
> Create a publication-quality scientific figure titled:
>
> **"The same cells can be represented in different feature spaces"**
>
> The figure should explain how our MDS MRD single-cell dataset can be examined from four complementary perspectives:
>
> 1. **Cell perspective in gene space:** A cell is represented by its expression across genes.
> 2. **Gene perspective:** A gene is represented by its expression across cells.
> 3. **Cell perspective in factor space:** The same cell is represented by learned latent factors.
> 4. **Factor perspective:** A factor is represented by its activity across cells.
>
> Crucially, each cell also has biological and clinical metadata:
>
> - Patient identity (P01, P02, etc.)
> - Malignancy label (malignant vs normal)
> - Cell type (`predicted.annotation`)
> - Potentially additional metadata, including timepoint and donor/recipient origin
>
> The main conceptual point is that **the feature representation changes, but the identity and biological annotations of each cell remain the same.**
>
> This should be an explanatory figure grounded in real data, not a classifier-performance figure.
>
> ## 1. Inspect the repository before implementation
>
> Find the relevant processed MRD AnnData objects and Stage 0–2 outputs.
>
> Identify:
>
> - Gene expression matrix and its normalization
> - Patient/sample identifiers
> - `CN.label` and donor/recipient labels
> - `predicted.annotation`
> - Existing Stage 1 factor representations (PCA, FA, NMF, etc.)
> - Relevant fitted models, gene loadings, and transformation parameters
>
> Inspect actual metadata categories before mapping them.
>
> Do not assume the location of files or the exact structure of `.obs`, `.var`, `.obsm`, or `.uns`.
>
> Use the existing processed data and models where possible. Do not refit Stage 1 unnecessarily.
>
> Produce a short audit describing which data and models were selected.
>
> ## 2. Figure layout
>
> Use a landscape canvas with two large matrices side by side.
>
> ### Left: Cell × Gene matrix
>
> \[
> X\in\mathbb{R}^{N\times G}
> \]
>
> Rows represent individual cells.
>
> Columns represent genes.
>
> Show a heatmap with a manageable number of representative cells and genes.
>
> Alongside the rows, display three annotation columns:
>
> | Patient | Malignancy | Cell type |
> |---|---|---|
> | P01 | Malignant | HSPC |
> | P01 | Normal | Myeloid |
> | P01 | Normal | T cell |
> | P02 | Malignant | HSPC |
> | P02 | Normal | B cell |
> | P03 | Malignant | Myeloid |
>
> These are illustrative categories only. Replace them with real observations.
>
> Group rows by patient, then distinguish malignant and normal cells within each patient. Preserve cell-type annotations.
>
> Use visually distinct patient group brackets and malignant/normal labels.
>
> ### Right: Cell × Factor matrix
>
> \[
> Z\in\mathbb{R}^{N\times K}
> \]
>
> Rows represent **exactly the same cells, in exactly the same order**.
>
> Columns represent learned factors.
>
> Repeat the patient, malignancy, and cell-type annotations.
>
> Show factor scores for these cells using a suitable existing Stage 1 representation.
>
> Between the matrices, show:
>
> **Stage 1: Learned representation**
>
> Gene expression → latent factor scores
>
> Indicate the actual dimensionality-reduction method used.
>
> Do not imply that all DR methods have identical mathematical properties.
>
> ## 3. Four interpretation panels
>
> Below the two matrices, create four compact explanatory panels.
>
> **A. Gene space — cell perspective (rows)**
>
> A single cell is represented by:
>
> \[
> x_i=(x_{i1},\ldots,x_{iG})
> \]
>
> Explain:
>
> - The cell belongs to a particular patient.
> - It has a malignant or normal label.
> - It has a cell-type annotation.
> - Its expression vector provides its molecular representation.
>
> Highlight one actual cell row in the heatmap.
>
> **B. Gene space — gene perspective (columns)**
>
> A single gene is represented by:
>
> \[
> X_{:,g}=(x_{1g},\ldots,x_{Ng})^\top
> \]
>
> Explain:
>
> - Gene expression varies across cells.
> - Variation may be associated with patient, cell type, malignancy, or other factors.
> - We can examine whether gene expression differences are shared across patients.
>
> Highlight one actual gene column.
>
> **C. Factor space — cell perspective (rows)**
>
> A single cell is represented by:
>
> \[
> z_i=(z_{i1},\ldots,z_{iK})
> \]
>
> Explain:
>
> - This is the same biological cell as in Panel A.
> - Its patient, malignancy, and cell-type labels are unchanged.
> - Only its feature representation has changed.
> - Factor scores summarize patterns learned from gene expression.
>
> Highlight the matching cell row.
>
> **D. Factor space — factor perspective (columns)**
>
> A single factor is represented by:
>
> \[
> Z_{:,k}=(z_{1k},\ldots,z_{Nk})^\top
> \]
>
> Explain:
>
> - A factor has scores across cells.
> - Its gene loadings describe how genes contribute to the factor.
> - It may capture coordinated biological variation.
> - Whether that variation relates to malignancy, cell type, or patient identity must be evaluated.
>
> Highlight one factor column.
>
> ## 4. Data selection and sampling
>
> The figure must remain readable.
>
> Select approximately 3–5 patients with sufficient malignant and normal cells, if available.
>
> Within each patient, sample cells to show meaningful combinations of:
>
> - Malignant versus normal
> - Cell-type annotations
> - Patient identity
>
> Use reproducible sampling with a fixed random seed.
>
> Prefer stratified sampling rather than sampling solely by cell abundance.
>
> Select approximately 20–40 genes for the displayed gene heatmap, and approximately 10–20 factors for the factor heatmap, adjusting for readability.
>
> Gene selection should follow an explicit, defensible criterion. Avoid choosing genes solely to manufacture visual separation.
>
> Factor selection should likewise be justified, and must not be based on held-out test labels.
>
> **Important:** If the chosen Stage 1 model is patient-specific, do not concatenate factor coordinates across patients and present them as a shared coordinate system. Either choose an existing shared representation or clearly distinguish patient-specific factor spaces.
>
> ## 5. Biological and statistical safeguards
>
> This is especially important.
>
> - Do not confuse malignant/normal status with cell type.
> - Do not assume that all malignant cells are HSPCs.
> - Do not equate recipient origin with malignancy without checking the actual labels.
> - Do not treat factor scores as direct measurements of biological pathways.
> - Do not interpret factor sign as inherently malignant or normal.
> - Do not imply that visually separated heatmap patterns demonstrate cross-patient generalization.
> - Do not use held-out labels to select or fit features if the figure is intended to illustrate a held-out pipeline.
>
> If the representation was learned transductively, explicitly label that fact.
>
> For any displayed expression transformation or factor-score scaling, explain whether it is for visualization only.
>
> Preserve the original row identities and verify that X and Z are aligned by cell identifier.
>
> ## 6. Visual style
>
> Use the attached reference illustration as a conceptual layout, not as a source of data.
>
> - White background
> - Dark navy text
> - Clean, BioRender-like scientific figure
> - Legible sans-serif fonts
> - Consistent patient colors across both matrices
> - Consistent malignant/normal label colors
> - Heatmap colors with clear legends
> - Clear dimension labels (N × G and N × K)
> - Minimal decorative elements
> - Adequate whitespace
> - No overlapping labels
>
> The figure should communicate that cells carry multiple annotations, while genes and factors provide different coordinate systems for describing those cells.
>
> ## 7. Implementation
>
> Use Python with appropriate scientific plotting libraries (Matplotlib, Seaborn, etc.).
>
> Prefer an implementation that integrates with the existing repository.
>
> Save:
>
> - A high-resolution PNG
> - A vector PDF or SVG
> - The plotting script
> - A small CSV containing the selected cell IDs and metadata
> - A CSV of displayed genes and factors
> - A short Markdown file explaining the data provenance, sampling, scaling, and model selection
>
> Make the figure reproducible with a fixed seed.
>
> Do not modify existing model artifacts or source data.
>
> ## 8. Validation
>
> Before finalizing, verify:
>
> 1. Both matrices contain identical cells in identical row order.
> 2. Patient identities agree across matrices.
> 3. Malignancy labels agree across matrices.
> 4. Cell-type annotations agree across matrices.
> 5. Factor values originate from the identified fitted Stage 1 representation.
> 6. The selected gene-expression layer and normalization are documented.
> 7. All figure labels and annotations match the underlying data.
>
> ## 9. Deliverables and review
>
> First inspect the repository and implement a reasonable initial version.
>
> Render the actual figure and inspect it for readability, clipping, annotation alignment, and scientific accuracy.
>
> Report:
>
> - Which patients and cells were selected
> - Which genes and factors were selected
> - Which Stage 1 representation was used
> - Whether it was learned across patients or separately per patient
> - What preprocessing and scaling were applied
> - Any scientific limitations of the visualization
>
> Do not perform new downstream modeling or change the Stage 0–2 pipeline unless necessary.
>
> **The immediate goal is a first data-grounded figure for scientific review, not a final biological conclusion.**
